Core Viewpoint - Zhuozheng Medical has successfully transitioned from loss to profit, marking a significant milestone with its listing on the Hong Kong Stock Exchange, showcasing a perfect growth trajectory for a private mid-to-high-end medical enterprise [3][4]. Group 1: Company Overview - Zhuozheng Medical officially listed on the Hong Kong Stock Exchange with a share price set at HKD 59, issuing 4.75 million shares and raising a total of HKD 285 million, with a net amount of HKD 209 million after expenses [3]. - The company has established a service network across 10 economically developed cities in China, operating 19 medical service institutions, including 17 clinics and 2 hospitals [3][4]. Group 2: Financial Performance - The company has shown consistent improvement in financial performance, with revenue increasing from CNY 473 million in 2022 to CNY 959 million in 2024, and gross profit rising from CNY 43.98 million to CNY 226 million during the same period [4]. - Zhuozheng Medical achieved a profit of CNY 80.23 million in 2024, marking its first profitable year, and continued this growth trend in the first eight months of 2025 with revenue of CNY 696 million and a profit of CNY 83.21 million [4]. Group 3: Market Position - According to Frost & Sullivan, Zhuozheng Medical ranks third among private mid-to-high-end comprehensive medical service providers in China, holding a market share of 2.0% based on 2024 revenue [4]. - The company stands out in a highly fragmented industry due to its extensive city coverage and large patient base, ranking first in the number of covered cities and second in patient visits among paid patients as of December 31, 2024 [4].
卓正医疗港股上市：开盘大涨35%，三次递表终登陆，业绩持续走高